Petrylak DP, et al. – In this report, the researchers presented preliminary data from Cohort 1 of EV-201—a pivotal, single-arm, two-cohort study—that included patients with locally advanced or metastatic urothelial cancer (la/mUC) with prior checkpoint inhibitor (CPI) and platinum-containing chemotherapy (Cohort 1) or a CPI and no prior chemotherapy (Cohort 2) who were treated with enfortumab vedotin (EV; an antibody-drug conjugate targeting Nectin-4, which is highly expressed in UC). Patients were given 1.25 mg/kg EV on Days 1, 8, and 15 of each 28-day cycle. The investigators noted a clinically meaningful ORR (the reported ORR was consistent with the phase 1 trial) in patients with la/mUC and prior platinum and CPI, including liver metastases pts, where there is a high unmet requirement. In these patients, EV demonstrated good tolerability and a manageable safety profile.